Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT03417882
Title GRN-1201 With Pembrolizumab in Subjects With Metastatic PD-L1+ NSCLC
Recruitment Active, not recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors BrightPath Biotherapeutics
Indications

lung non-small cell carcinoma

Therapies

GRN-1201 + Pembrolizumab

Age Groups: adult | senior
Covered Countries USA


No variant requirements are available.